Title

Post Covid rhino - Orbital cerebral mucormycosis among Indian patients

Authors

Rashmi Rani Bharti¹, Kshiti Atreya¹, Kumari Sunny¹, Deepak Kumar² & Bharti Kumari^1,*

Affiliation

¹Department of Pathology, IGIMS, Patna, Bihar, India; ²Department of Radiodiagnosis, IGIMS, Patna, Bihar, India; *Corresponding author

Email

Rashmi Rani Bharti - E-mail: rashmi.99.rims@gmail.com
Kshiti Atreya - E-mail: kshitiatreya24@gmail.com
Kumari Sunny - E-mail: drsunnyskmch@gmail.com
Deepak Kumar - E-mail: 1999deepak@gmail.com
Bharti Kumari - E-mail: bchoudhary1012@gmail.com
 

Article Type

Research Article

Date

Received May 1, 2025; Revised May 31, 2025; Accepted May 31, 2025, Published May 31, 2025

Abstract

The clinical profile, risk factors, diagnostic methods, therapeutic interventions and outcomes of post-COVID rhino-orbital cerebral mucormycosis (ROCM) cases in a tertiary care center in Eastern India is of interest.  This prospective study included 102 post-COVID patients diagnosed with rhino-orbital cerebral mucormycosis over one year at a tertiary care center. Clinical data, imaging, microbiological findings, treatments and outcomes were recorded. All patients received antifungal therapy, with surgical intervention as needed.  Out of 102 post-COVID patients diagnosed with rhino-orbital cerebral mucormycosis, 79.4% had diabetes mellitus and 85.3% had a history of corticosteroid use. Orbital involvement was seen in 74.5% of patients, with cerebral extension in 33.3%. Surgical intervention was required in 76.4% of cases and the overall mortality rate was 18.6%. Post-COVID mucormycosis is a rapidly progressive and life-threatening infection strongly associated with diabetes and corticosteroid use. Early diagnosis, prompt antifungal therapy and timely surgical intervention are critical for improving outcomes.

Keywords

Post COVID-19 complications, Rhino-orbital cerebral mucormycosis, COVID-associated mucormycosis (CAM),   Fungal infections in COVID-19,   Tertiary healthcare center study, Immunocompromised infections, Diabetes and mucormycosis, COVID-19 secondary infection

Citation

Bharti et al. Bioinformation 21(5): 1290-1294 (2025)

Edited by

Neelam Goyal & Shruti Dabi

ISSN

0973-2063

Publisher

Biomedical Informatics

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.